- United Kingdom
- /
- Healthtech
- /
- AIM:COG
Cambridge Cognition Holdings Full Year 2022 Earnings: EPS Misses Expectations
Cambridge Cognition Holdings (LON:COG) Full Year 2022 Results
Key Financial Results
- Revenue: UK£12.6m (up 25% from FY 2021).
- Net loss: UK£409.0k (down by 191% from UK£450.0k profit in FY 2021).
- UK£0.013 loss per share (down from UK£0.014 profit in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cambridge Cognition Holdings EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Healthcare Services industry in the United Kingdom.
Performance of the British Healthcare Services industry.
The company's shares are down 2.0% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Cambridge Cognition Holdings that you should be aware of before investing here.
If you're looking to trade Cambridge Cognition Holdings, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:COG
Cambridge Cognition Holdings
A neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally.
Undervalued slight.
Market Insights
Community Narratives

